BPC-157 is banned in competitive sports and sits in a regulatory gray zone everywhere else. The World Anti-Doping Agency added it to its Prohibited List in 2022, and since then, the FDA and Australia’s drug regulator have both taken steps to restrict its availability. Whether you’re an athlete, someone considering it for injury recovery, or just curious about its legal status, the answer depends on where you are and what you plan to do with it.
Banned in All Competitive Sports Since 2022
WADA placed BPC-157 on its 2022 Prohibited List under the S0 Unapproved Substances category. This means it’s prohibited both in and out of competition, year-round. Before 2022, athletes could technically use it without violating anti-doping rules, but that window is now closed.
The S0 category is reserved for substances that have no current approval by any governmental regulatory health authority for human therapeutic use. It’s a catch-all designed to prevent athletes from gaining an edge with experimental compounds. If you compete in any sport governed by WADA, USADA, or a national anti-doping organization, testing positive for BPC-157 can result in a suspension. USADA has explicitly warned athletes to avoid any product marketed as “research only,” noting that some websites selling BPC-157 label it this way while simultaneously providing dosing instructions for human use.
FDA Status in the United States
BPC-157 is not an FDA-approved drug. It does not appear in the FDA’s Approved Drugs database under any name. It’s also not recognized as a dietary ingredient, which means it cannot legally be sold as a supplement. This leaves it in a category where no standard legal pathway exists for prescribing or purchasing it.
The bigger regulatory move came in September 2023, when the FDA classified BPC-157 as a Category 2 bulk drug substance. That classification effectively barred compounding pharmacies from using it in custom medications, citing concerns about safety, impurities, and the near-total absence of human clinical data. Before this, some physicians had been working with compounding pharmacies to provide BPC-157 to patients, but the FDA’s action put those arrangements on shaky legal ground.
The situation has shifted again since then. The FDA removed BPC-157 from Category 2 after the original nominators withdrew their requests. However, the agency has announced it intends to consult its Pharmacy Compounding Advisory Committee in July 2026 on whether two specific forms of the substance (BPC-157 acetate and BPC-157 free base) should be added to the approved compounding list. Until that review concludes, the regulatory status remains unsettled. The FDA has not explicitly banned BPC-157 outright, but it has made clear there is currently no legal basis for selling it as a drug, food, supplement, or compounded medication.
Australia Classified It as a Prescription-Only Poison
Australia took a more definitive step. In November 2023, the Therapeutic Goods Administration placed BPC-157 into Schedule 4, which covers prescription-only medicines. More significantly, they added it to Appendix D, clause 5, making possession without authority illegal. This change took effect on June 1, 2024.
The decision was prompted by 48 referrals for importation of BPC-157 received by the TGA since July 2022. Australia’s approach aligns BPC-157 with other performance- and image-enhancing substances. If you’re in Australia, possessing BPC-157 without a valid prescription is now a criminal matter, not just a regulatory technicality.
Importing BPC-157 for Personal Use
Ordering BPC-157 from overseas and having it shipped to you carries real risk. Under FDA rules, importing an unapproved drug into the United States is illegal in most circumstances. The agency can and does refuse shipments at the border when a product has no domestic approval, appears to present a health risk, or looks like it’s intended for commercial distribution.
The FDA does exercise some discretion with personal imports, occasionally allowing small quantities of unapproved drugs through when they’re for a serious condition with no domestic treatment option, pose no unreasonable risk, and are limited to roughly a three-month supply. But BPC-157 doesn’t fit neatly into those exceptions. It has no approved use anywhere, it’s been flagged for safety concerns, and the FDA has specifically cautioned against compounded versions due to potential contamination. A package could be seized at customs with little recourse.
What’s Actually Sold Online
Despite its regulatory status, BPC-157 remains widely available through online vendors. Most of these products are labeled as “research chemicals” with disclaimers like “not for human consumption” or “for research purposes only.” This labeling is a legal strategy, not a guarantee of quality or safety. USADA and the FDA’s Operation Supplement Safety program have both noted that these disclaimers coexist with marketing clearly aimed at human users.
The lack of FDA oversight means there’s no guarantee that what you’re buying actually contains BPC-157, contains the amount listed on the label, or is free from contaminants. This is one of the FDA’s core safety concerns: without manufacturing standards, purity and dosing are unknowns.
Why Regulators Are Cautious
The fundamental issue is that almost no human data exists. Only three published clinical studies have tested BPC-157 in humans. The vast majority of evidence comes from animal studies, primarily in rats, where the peptide has shown effects on tendon healing, gut repair, and tissue recovery. Those results generated significant interest in fitness and wellness communities, but animal findings frequently don’t translate to humans in the same way, at the same doses, or with the same safety profile.
Regulators aren’t saying BPC-157 is definitively dangerous. They’re saying no one has done the work to prove it’s safe for human use, and until that work is done, the compound doesn’t meet the threshold for legal sale or prescription. The FDA’s upcoming 2026 review of BPC-157 for compounding could change the landscape, but for now, anyone using it is doing so without the safety net of clinical approval or quality control.